IBAB Ion Beam Applications SA

IBA launches QUASAR® GRID3D Advantage Image Distortion Analysis System

IBA launches QUASAR® GRID3D Advantage Image Distortion Analysis System

New standard in the Quality Assurance of image distortion for MR guided radiation therapy and MR simulation in planning

Louvain-la-Neuve, Belgium, 3 May 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global leading provider of dosimetry and quality assurance (QA) solutions, today announces the launch of its QUASAR® GRID3D Advantage Image Distortion Analysis System at the European Society for Radiotherapy and Oncology (ESTRO) 2025 Annual Congress in Vienna, Austria.

This advanced product is uniquely designed for facilities requiring precise Magnetic Resonance (MR) distortion analysis for stereotactic planning, ensuring confidence in geometric fidelity for MR images. It combines automated analysis through user-friendly software with a versatile multi-use solution including various frame adapters or frameless options.

MR is increasingly used in radiation therapy due to its ability to provide superior soft tissue contrast without ionizing radiation. In MR-guided radiation therapy, precise imaging is critical for targeting tumors and protecting surrounding healthy tissue. However, MR images can be subject to geometric distortions that may compromise treatment accuracy. Robust QA tools like GRID3D Advantage are essential to ensure image fidelity and improve clinical confidence.

Ian Paddick, Director at Medical Physics Limited, said: “For the first time, the gold standard of measuring image distortion using the Known Target Method is available for the Vantage Frame setup. This represents a huge step forward in our ability to provide comprehensive QA for Gamma Knife® radiosurgery.”

Jean-Marc Bothy, President of IBA Dosimetry, commented: “We understand that MR simulation has become an integral part of radiation therapy workflows, especially for small field cases where millimeters can impact treatment outcomes. As a result, geometric distortion QA is no longer optional but essential. GRID3D Advantage reflects our dedication to providing clinicians and researchers with accurate and precise tools to evaluate MRI 3D geometric distortion.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

CONTACTS

Olivier Lechien

Corporate Communication Director



ICR Healthcare

Amber Fennell, Angela Gray, Chris Welsh

+44 (0) 20 3709 5700

Attachment



EN
03/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA launches QUASAR® GRID3D Advantage Image Distortion Analysis System

IBA launches QUASAR® GRID3D Advantage Image Distortion Analysis System New standard in the Quality Assurance of image distortion for MR guided radiation therapy and MR simulation in planning Louvain-la-Neuve, Belgium, 3 May 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global leading provider of dosimetry and quality assurance (QA) solutions, today announces the launch of its QUASAR® GRID3D Advantage Image Distortion Analysis System at the European Society for Radiotherapy and Oncology (ESTRO) 2025 Annual Congress in Vienna, Au...

 PRESS RELEASE

IBA lance QUASAR® GRID3D Advantage, un système d'analyse de distorsion...

IBA lance QUASAR® GRID3D Advantage, un système d'analyse de distorsion d'image Nouvelle norme pour l'assurance qualité de la distorsion de l'image pour la radiothérapie guidée par résonnance magnétique et la simulation de plan de traitement Louvain-la-Neuve, Belgique, le 3 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et l'un des principaux fournisseurs de solutions de dosimétrie et d'assurance qualité (QA), annonce aujourd'hui le lancement de son système d’analyse de distorsion d’image QUASAR® GRID3D Advantage lors d...

 PRESS RELEASE

IBA launches myQA Blue Phantom³ for radiation therapy quality assuranc...

IBA launches myQA Blue Phantom³ for radiation therapy quality assurance Fastest automatic levelling offering on the market Seamless integration with all linear accelerators Louvain-la-Neuve, Belgium, 2 May 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a leading provider of dosimetry and quality assurance (QA) solutions, announces the launch of myQA Blue Phantom³ at the European Society for Radiotherapy and Oncology (ESTRO) 2025 annual congress in Vienna, Austria. This innovative solution is set to transform the field of radiother...

 PRESS RELEASE

IBA lance myQA Blue Phantom³ pour l'assurance qualité en radiothérapie

IBA lance myQA Blue Phantom³ pour l'assurance qualité en radiothérapie L'offre de nivellement automatique la plus rapide du marché Intégration aisée avec tous les accélérateurs linéaires Louvain-la-Neuve, Belgique, le 2 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et l'un des principaux fournisseurs de solutions de dosimétrie et d'assurance qualité (QA), annonce le lancement de myQA Blue Phantom³ lors du congrès annuel 2025 de la Société européenne de radiothérapie et d'oncologie (ESTRO) à Vienne, en Autriche. Cette ...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Immediate Release – April 28th, 2025 Louvain-la-Neuve, Belgium, April 28th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from Marc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch